Longitudinal studies of dogs with cancer as a comparative oncology model
Ended Awarded Last action
- Contract number
- 75N91022F00020
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $168,916
Award facts
- Contract value 100% obligated
- $168,916.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21703, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$3,154,268 | |
| Terminate for Convenience | $0 | |
| Original award | $3,323,184 |
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on September 9, 2022, with a ceiling value of $168,916.00 under a cost-plus-fixed-fee pricing structure for longitudinal studies of dogs with cancer as a comparative oncology model.
Place of performance is Frederick, Maryland. The order has an ultimate completion date of September 8, 2026. Service Contract Inventory reporting shows minimal labor footprint across the performance period: $85,000 invoiced in FY2022, declining to $9,000 in FY2023 (64 contractor hours at $146.94/hr) and $9,000 in FY2024 (93 contractor hours at $95.28/hr), with $6,000 invoiced in FY2025. No FTEs were reported in FY2023 forward, and Leidos Biomedical Research self-performed all reported hours without subcontractor engagement on this order.
Quick answers
Who was awarded contract 75N91022F00020?
75N91022F00020 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 9, 2022.
How much is contract 75N91022F00020 worth?
The government has obligated $168,916 on 75N91022F00020.
Is contract 75N91022F00020 an order under another contract?
Yes. 75N91022F00020 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00020 competed?
The extent of competition for 75N91022F00020 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award